Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
upifitamab rilsodotin + carboplatin
- Development stage
- Unknown
- Lead developer
- Mersana Therapeutics
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Upifitamab rilsodotin + carboplatin is a combination of an antibody-drug conjugate (ADC), upifitamab rilsodotin (XMT-1536, UpRi), with the platinum-based chemotherapy agent carboplatin. Upifitamab rilsodotin targets the sodium-dependent phosphate transporter NaPi2b, which is overexpressed in several solid tumors, notably high-grade serous ovarian, fallopian tube, and primary peritoneal cancer, and delivers a highly potent cytotoxic auristatin-derived payload (using the Dolaflexin platform) that induces immunogenic cell death. Carboplatin is a DNA-damaging agent that crosslinks DNA, thereby inhibiting replication and transcription, leading to cell death. The combination is being investigated primarily in patients with high-grade serous ovarian cancer who have previously received platinum-based therapies[1][2][3][5][6].
- Other names
- upifitamab rilsodotin + carboplatin
02
Targets
TUBB (Tubulin (alpha and beta subunits))SLC34A2 (Sodium-dependent phosphate transporter type IIb)DNA
Beyond the preview
Go deeper on upifitamab rilsodotin + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on upifitamab rilsodotin + carboplatin.